Clinical Trials
90 trialsNCT05173142 2026-05-15
A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT05516914 2026-04-01
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Completed
NCT00066443 2026-03-27
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT04381832 2025-07-22
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
Arcus Biosciences, Inc.
Phase 1/2 Completed
NCT02039336 2025-07-08
M13DAP
The Netherlands Cancer Institute
Phase 1/2 Completed
NCT04256707 2025-03-19
SPRINT
Karyopharm Therapeutics Inc
Phase 1/2 Completed
NCT04276493 2024-12-06
Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab
BeiGene
Phase 1/2 Completed
NCT02229084 2024-11-07
Vaccination of High Risk Breast Cancer Patients
University of Arkansas
Phase 1/2 Completed
NCT03693612 2024-08-28
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
GlaxoSmithKline
Phase 1/2 Completed
NCT02735239 2024-03-22
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02718820 2024-01-09
Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Medical University of Vienna
Phase 1/2 Completed
NCT02834403 2023-12-15
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
The Methodist Hospital Research Institute
Phase 1/2 Completed
NCT02599324 2023-11-18
Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors
Pharmacyclics LLC.
Phase 1/2 Completed
NCT01234025 2023-10-06
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)
Ionis Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT03840915 2023-08-21
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 1/2 Completed
NCT03636256 2023-08-14
Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Phase 1/2 Completed
NCT02324543 2023-07-21
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT05116891 2023-07-03
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Cantargia AB
Phase 1/2 Completed
NCT01824901 2023-06-29
Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 1/2 Completed
NCT00129896 2023-03-06
Neoadjuvant Chemotherapy With Myocet/Taxotere/Herceptin for HER2 Positive Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 1/2 Completed
NCT01879085 2022-09-21
GemTax
University of Pittsburgh
Phase 1/2 Completed
NCT02494921 2022-08-31
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
University of California, San Francisco
Phase 1/2 Completed
NCT02447406 2022-06-15
Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
Samsung Medical Center
Phase 1/2 Completed
NCT02659020 2022-05-09
ANNOUNCE 2
Eli Lilly and Company
Phase 1/2 Completed
NCT00193128 2021-11-24
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT01217060 2021-04-13
Trimodality Management of T1b Esophageal Cancers
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01468532 2021-03-25
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT03606928 2020-03-20
mFLOT Chemotherapy as First-line Treatment in GC
Ruijin Hospital
Phase 1/2 Completed
NCT01683994 2019-11-08
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00456989 2019-10-30
Study of Taxotere and Doxil to Treat Advanced Androgen-Independent Prostate Cancer
University of Louisville
Phase 1/2 Completed
NCT01084655 2019-07-30
Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer
Takeda
Phase 1/2 Completed
NCT00669162 2019-07-24
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT00436501 2019-02-26
VEGF Trap and Docetaxel in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00711243 2019-02-26
Docetaxel, Oxaliplatin, and Fluorouracil in Treating Patients With Metastatic or Unresectable Stomach Cancer, Gastroesophageal Junction Cancer, or Other Solid Tumor
Northwestern University
Phase 1/2 Completed
NCT00318890 2019-02-05
Cisplatin and Docetaxel Plus Docetaxel and Radiotherapy With Amifostine for Squamous Cell Carcinoma of the Head and Neck
University of Alabama at Birmingham
Phase 1/2 Completed
NCT00390429 2018-12-06
Docetaxel and Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
University of California, Davis
Phase 1/2 Completed
NCT00498953 2018-07-09
Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed
NCT01204099 2018-05-16
Study of PX-866 and Docetaxel in Solid Tumors
Seagen Inc.
Phase 1/2 Completed
NCT01921673 2017-07-14
Dovitinib Plus Docetaxel in Gastric Cancer
Asan Medical Center
Phase 1/2 Completed
NCT00225420 2017-06-01
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00574769 2017-04-11
Safety Study & Effectiveness of Docetaxel With RAD001 and Bevacizumab in Men With Advanced Prostate Cancer
University of Southern California
Phase 1/2 Completed
NCT00934856 2017-04-06
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 1/2 Completed
NCT00086957 2017-02-27
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
City of Hope Medical Center
Phase 1/2 Completed
NCT01106352 2017-01-04
A Study of Alpharadin With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC)
Bayer
Phase 1/2 Completed
NCT00526110 2016-10-31
Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00405951 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00450892 2016-07-07
Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1/2 Completed